02922nam 2200625Ia 450 991078062820332120230721023923.00-19-173987-10-19-960699-41-283-58075-697866138932080-19-157517-8(CKB)2430000000022719(EBL)975599(OCoLC)801363649(SSID)ssj0000352951(PQKBManifestationID)11270462(PQKBTitleCode)TC0000352951(PQKBWorkID)10286032(PQKB)10068149(MiAaPQ)EBC975599(StDuBDS)EDZ0000091504(Au-PeEL)EBL975599(CaPaEBR)ebr10581391(CaONFJC)MIL389320(EXLCZ)99243000000002271920070920d2007 uy 0engur|n|---|||||txtccrEndocrine therapies in breast cancer[electronic resource] /edited by Aman U. BuzdarOxford ;New York Oxford University Press20071 online resource (129 p.)Oxford oncology libraryDescription based upon print version of record.0-19-921814-5 Includes bibliographical references and index.Contents; Contributors; 1 Selection of patients for endocrine therapies; 2 Ovarian ablation; 3 Antioestrogens; 4 Aromatase inhibitors in early and advanced disease; 5 Fulvestrant in metastatic disease; 6 Progestins and androgens; 7 Combined endocrine and chemotherapy in breast cancer; 8 Hormone replacement therapy in patients with a prior history of breast cancer; 9 Chemoprevention; Index; A; B; C; D; E; F; G; H; I; L; M; N; O; P; R; S; T; V; W; ZBreast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromatase inhibitors are able toreduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen. New and emerging Oxford oncology library.BreastCancerHormone therapyBreastCancerEndocrine aspectsBreastCancerHormone therapy.BreastCancerEndocrine aspects.616.99/449071Buzdar Aman U1564342MiAaPQMiAaPQMiAaPQBOOK9910780628203321Endocrine therapies in breast cancer3833346UNINA